#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=Echinochrome A ( Ech A ) is a dark red pigment separated from sea urchin shell and spine and has a chemical structure of 6-ethyl-2,3,5,7,8-pentahydroxy-1,4-naphthoquinone .
3-1	17-29	Echinochrome	substance	new	appos	3-2[4_0]
3-2	30-31	A	abstract[4]	giv[4]	coref	3-8[5_4]
3-3	32-33	(	abstract[4]	giv[4]	_	_
3-4	34-37	Ech	abstract[4]	giv[4]	_	_
3-5	38-39	A	abstract[4]	giv[4]	_	_
3-6	40-41	)	abstract[4]	giv[4]	_	_
3-7	42-44	is	_	_	_	_
3-8	45-46	a	substance[5]	giv[5]	coref	5-7[0_5]
3-9	47-51	dark	substance[5]	giv[5]	_	_
3-10	52-55	red	substance[5]	giv[5]	_	_
3-11	56-63	pigment	substance[5]	giv[5]	_	_
3-12	64-73	separated	_	_	_	_
3-13	74-78	from	_	_	_	_
3-14	79-82	sea	place|object[8]	new|new[8]	_	_
3-15	83-89	urchin	animal|object[8]	new|new[8]	_	_
3-16	90-95	shell	object[8]	new[8]	_	_
3-17	96-99	and	_	_	_	_
3-18	100-105	spine	object	new	_	_
3-19	106-109	and	_	_	_	_
3-20	110-113	has	_	_	_	_
3-21	114-115	a	abstract[10]	new[10]	_	_
3-22	116-124	chemical	abstract[10]	new[10]	_	_
3-23	125-134	structure	abstract[10]	new[10]	_	_
3-24	135-137	of	abstract[10]	new[10]	_	_
3-25	138-187	6-ethyl-2,3,5,7,8-pentahydroxy-1,4-naphthoquinone	abstract[10]|substance	new[10]|new	_	_
3-26	188-189	.	_	_	_	_

#Text=As a main active component of a commercial therapeutic agent called ‘ histochrome ’ , Ech A has been used for the treatment of cardiovascular disorders and ophthalmopathic complications in Russia .
4-1	190-192	As	_	_	_	_
4-2	193-194	a	_	_	_	_
4-3	195-199	main	_	_	_	_
4-4	200-206	active	_	_	_	_
4-5	207-216	component	_	_	_	_
4-6	217-219	of	_	_	_	_
4-7	220-221	a	object[12]	new[12]	_	_
4-8	222-232	commercial	object[12]	new[12]	_	_
4-9	233-244	therapeutic	object[12]	new[12]	_	_
4-10	245-250	agent	object[12]	new[12]	_	_
4-11	251-257	called	_	_	_	_
4-12	258-259	‘	abstract[13]	new[13]	_	_
4-13	260-271	histochrome	abstract[13]	new[13]	_	_
4-14	272-273	’	abstract[13]	new[13]	_	_
4-15	274-275	,	_	_	_	_
4-16	276-279	Ech	person	new	coref	6-3[23_0]
4-17	280-281	A	_	_	_	_
4-18	282-285	has	_	_	_	_
4-19	286-290	been	_	_	_	_
4-20	291-295	used	_	_	_	_
4-21	296-299	for	_	_	_	_
4-22	300-303	the	abstract[15]	new[15]	coref	9-6[65_15]
4-23	304-313	treatment	abstract[15]	new[15]	_	_
4-24	314-316	of	abstract[15]	new[15]	_	_
4-25	317-331	cardiovascular	abstract[15]|abstract|abstract[17]	new[15]|new|new[17]	_	_
4-26	332-341	disorders	abstract[15]|abstract[17]	new[15]|new[17]	_	_
4-27	342-345	and	abstract[15]	new[15]	_	_
4-28	346-361	ophthalmopathic	abstract[15]|abstract[18]	new[15]|new[18]	_	_
4-29	362-375	complications	abstract[15]|abstract[18]	new[15]|new[18]	_	_
4-30	376-378	in	abstract[15]|abstract[18]	new[15]|new[18]	_	_
4-31	379-385	Russia	abstract[15]|abstract[18]|place	new[15]|new[18]|new	_	_
4-32	386-387	.	_	_	_	_

#Text=Among the several biological benefits of Ech A , anti-oxidant and anti-inflammatory capacity is proposed as a major underlying therapeutic mechanism .
5-1	388-393	Among	_	_	_	_
5-2	394-397	the	abstract[20]	new[20]	_	_
5-3	398-405	several	abstract[20]	new[20]	_	_
5-4	406-416	biological	abstract[20]	new[20]	_	_
5-5	417-425	benefits	abstract[20]	new[20]	_	_
5-6	426-428	of	abstract[20]	new[20]	_	_
5-7	429-432	Ech	abstract[20]|abstract	new[20]|giv	coref	6-41
5-8	433-434	A	abstract[22]	new[22]	_	_
5-9	435-436	,	abstract[22]	new[22]	_	_
5-10	437-449	anti-oxidant	abstract[22]	new[22]	_	_
5-11	450-453	and	abstract[22]	new[22]	_	_
5-12	454-471	anti-inflammatory	abstract[22]	new[22]	_	_
5-13	472-480	capacity	abstract[22]	new[22]	_	_
5-14	481-483	is	_	_	_	_
5-15	484-492	proposed	_	_	_	_
5-16	493-495	as	_	_	_	_
5-17	496-497	a	_	_	_	_
5-18	498-503	major	_	_	_	_
5-19	504-514	underlying	_	_	_	_
5-20	515-526	therapeutic	_	_	_	_
5-21	527-536	mechanism	_	_	_	_
5-22	537-538	.	_	_	_	_

#Text=Indeed , Ech A has been shown to attenuate the oxidative stress caused by reactive oxygen species ( ROS ) and cardiac toxic drugs , providing mitochondrial protection of cardiomyocyte . Park et al. have reported similar observations showing that Ech A reduced both cellular and mitochondrial ROS levels of patient-derived cardiac progenitors during the oxidative stress situation .
6-1	539-545	Indeed	_	_	_	_
6-2	546-547	,	_	_	_	_
6-3	548-551	Ech	person[23]	giv[23]	coref	15-8[0_23]
6-4	552-553	A	person[23]	giv[23]	_	_
6-5	554-557	has	_	_	_	_
6-6	558-562	been	_	_	_	_
6-7	563-568	shown	_	_	_	_
6-8	569-571	to	_	_	_	_
6-9	572-581	attenuate	_	_	_	_
6-10	582-585	the	abstract[24]	new[24]	coref	6-57[0_24]
6-11	586-595	oxidative	abstract[24]	new[24]	_	_
6-12	596-602	stress	abstract[24]	new[24]	_	_
6-13	603-609	caused	_	_	_	_
6-14	610-612	by	_	_	_	_
6-15	613-621	reactive	abstract[26]	new[26]	_	_
6-16	622-628	oxygen	substance|abstract[26]	new|new[26]	_	_
6-17	629-636	species	abstract[26]	new[26]	_	_
6-18	637-638	(	_	_	_	_
6-19	639-642	ROS	substance	new	coref	6-48
6-20	643-644	)	_	_	_	_
6-21	645-648	and	_	_	_	_
6-22	649-656	cardiac	substance[28]	new[28]	_	_
6-23	657-662	toxic	substance[28]	new[28]	_	_
6-24	663-668	drugs	substance[28]	new[28]	_	_
6-25	669-670	,	_	_	_	_
6-26	671-680	providing	_	_	_	_
6-27	681-694	mitochondrial	abstract|abstract[30]	new|new[30]	coref|coref	6-47|6-47
6-28	695-705	protection	abstract[30]	new[30]	_	_
6-29	706-708	of	abstract[30]	new[30]	_	_
6-30	709-722	cardiomyocyte	abstract[30]|object	new[30]|new	_	_
6-31	723-724	.	_	_	_	_
6-32	725-729	Park	person	new	_	_
6-33	730-732	et	_	_	_	_
6-34	733-736	al.	_	_	_	_
6-35	737-741	have	_	_	_	_
6-36	742-750	reported	_	_	_	_
6-37	751-758	similar	abstract[33]	new[33]	_	_
6-38	759-771	observations	abstract[33]	new[33]	_	_
6-39	772-779	showing	_	_	_	_
6-40	780-784	that	_	_	_	_
6-41	785-788	Ech	abstract	giv	coref	7-7[44_0]
6-42	789-790	A	abstract[35]	new[35]	_	_
6-43	791-798	reduced	abstract[35]	new[35]	_	_
6-44	799-803	both	abstract[35]	new[35]	_	_
6-45	804-812	cellular	abstract[35]	new[35]	_	_
6-46	813-816	and	_	_	_	_
6-47	817-830	mitochondrial	abstract	giv	_	_
6-48	831-834	ROS	substance|abstract[38]	giv|new[38]	coref|coref|coref|coref	8-24[62_38]|9-10|8-24[62_38]|9-10
6-49	835-841	levels	abstract[38]	new[38]	_	_
6-50	842-844	of	abstract[38]	new[38]	_	_
6-51	845-860	patient-derived	abstract[38]|object[40]	new[38]|new[40]	_	_
6-52	861-868	cardiac	abstract[38]|person|object[40]	new[38]|new|new[40]	_	_
6-53	869-880	progenitors	abstract[38]|object[40]	new[38]|new[40]	_	_
6-54	881-887	during	abstract[38]|object[40]	new[38]|new[40]	_	_
6-55	888-891	the	abstract[38]|object[40]|event[42]	new[38]|new[40]|new[42]	_	_
6-56	892-901	oxidative	abstract[38]|object[40]|event[42]	new[38]|new[40]|new[42]	_	_
6-57	902-908	stress	abstract[38]|object[40]|abstract|event[42]	new[38]|new[40]|giv|new[42]	_	_
6-58	909-918	situation	abstract[38]|object[40]|event[42]	new[38]|new[40]|new[42]	_	_
6-59	919-920	.	_	_	_	_

#Text=The anti-oxidative and anti-viral activity of Ech A has also been proved in vitro using a tick-borne encephalitis virus and herpes simplex virus type 1-infected cell models .
7-1	921-924	The	abstract[43]	new[43]	_	_
7-2	925-939	anti-oxidative	abstract[43]	new[43]	_	_
7-3	940-943	and	abstract[43]	new[43]	_	_
7-4	944-954	anti-viral	abstract[43]	new[43]	_	_
7-5	955-963	activity	abstract[43]	new[43]	_	_
7-6	964-966	of	abstract[43]	new[43]	_	_
7-7	967-970	Ech	abstract[43]|abstract[44]	new[43]|giv[44]	coref	8-5[54_44]
7-8	971-972	A	abstract[43]|abstract[44]	new[43]|giv[44]	_	_
7-9	973-976	has	_	_	_	_
7-10	977-981	also	_	_	_	_
7-11	982-986	been	_	_	_	_
7-12	987-993	proved	_	_	_	_
7-13	994-996	in	_	_	_	_
7-14	997-1002	vitro	_	_	_	_
7-15	1003-1008	using	_	_	_	_
7-16	1009-1010	a	abstract[46]|abstract[47]	new[46]|new[47]	coref|coref|coref|coref	7-23[0_46]|11-19[93_47]|7-23[0_46]|11-19[93_47]
7-17	1011-1021	tick-borne	abstract[46]|abstract[47]	new[46]|new[47]	_	_
7-18	1022-1034	encephalitis	abstract|abstract[46]|abstract[47]	new|new[46]|new[47]	_	_
7-19	1035-1040	virus	abstract[46]|abstract[47]	new[46]|new[47]	_	_
7-20	1041-1044	and	abstract[47]	new[47]	_	_
7-21	1045-1051	herpes	abstract[47]|person|abstract[51]	new[47]|new|new[51]	_	_
7-22	1052-1059	simplex	abstract[47]|place|abstract[51]	new[47]|new|new[51]	_	_
7-23	1060-1065	virus	abstract[47]|abstract|abstract[51]	new[47]|giv|new[51]	_	_
7-24	1066-1070	type	abstract[47]|abstract[51]	new[47]|new[51]	_	_
7-25	1071-1081	1-infected	_	_	_	_
7-26	1082-1086	cell	abstract[52]	new[52]	_	_
7-27	1087-1093	models	abstract[52]	new[52]	_	_
7-28	1094-1095	.	_	_	_	_

#Text=The therapeutic potential of Ech A was also evaluated in an experimental gastric ulcer model where Ech A provided anti-ulcerogenic effects by increasing endogenous enzymatic and non-enzymatic antioxidant levels in vivo .
8-1	1096-1099	The	abstract[53]	new[53]	_	_
8-2	1100-1111	therapeutic	abstract[53]	new[53]	_	_
8-3	1112-1121	potential	abstract[53]	new[53]	_	_
8-4	1122-1124	of	abstract[53]	new[53]	_	_
8-5	1125-1128	Ech	abstract[53]|substance[54]	new[53]|giv[54]	coref	8-17[0_54]
8-6	1129-1130	A	abstract[53]|substance[54]	new[53]|giv[54]	_	_
8-7	1131-1134	was	_	_	_	_
8-8	1135-1139	also	_	_	_	_
8-9	1140-1149	evaluated	_	_	_	_
8-10	1150-1152	in	_	_	_	_
8-11	1153-1155	an	abstract[57]	new[57]	coref	9-22[74_57]
8-12	1156-1168	experimental	abstract[57]	new[57]	_	_
8-13	1169-1176	gastric	abstract|abstract[57]	new|new[57]	_	_
8-14	1177-1182	ulcer	person|abstract[57]	new|new[57]	_	_
8-15	1183-1188	model	abstract[57]	new[57]	_	_
8-16	1189-1194	where	_	_	_	_
8-17	1195-1198	Ech	substance	giv	coref	9-5
8-18	1199-1200	A	abstract[59]	new[59]	coref	13-27[115_59]
8-19	1201-1209	provided	abstract[59]	new[59]	_	_
8-20	1210-1226	anti-ulcerogenic	abstract[59]	new[59]	_	_
8-21	1227-1234	effects	abstract[59]	new[59]	_	_
8-22	1235-1237	by	_	_	_	_
8-23	1238-1248	increasing	_	_	_	_
8-24	1249-1259	endogenous	substance[60]|abstract[62]	new[60]|giv[62]	_	_
8-25	1260-1269	enzymatic	substance[60]|abstract[62]	new[60]|giv[62]	_	_
8-26	1270-1273	and	abstract[62]	giv[62]	_	_
8-27	1274-1287	non-enzymatic	abstract[62]	giv[62]	_	_
8-28	1288-1299	antioxidant	person|abstract[62]	new|giv[62]	_	_
8-29	1300-1306	levels	abstract[62]	giv[62]	_	_
8-30	1307-1309	in	abstract[62]	giv[62]	_	_
8-31	1310-1314	vivo	abstract[62]	giv[62]	_	_
8-32	1315-1316	.	_	_	_	_

#Text=In another study , Ech A treatment could reduce ROS production and pro-inflammatory tumor necrosis factor-α ( TNF-α ) secretion in a rat model of acute uveitis induced by lipopolysaccharide injection .
9-1	1317-1319	In	_	_	_	_
9-2	1320-1327	another	abstract[63]	new[63]	coref	15-2[122_63]
9-3	1328-1333	study	abstract[63]	new[63]	_	_
9-4	1334-1335	,	_	_	_	_
9-5	1336-1339	Ech	substance	giv	coref	10-6[78_0]
9-6	1340-1341	A	abstract[65]	giv[65]	_	_
9-7	1342-1351	treatment	abstract[65]	giv[65]	_	_
9-8	1352-1357	could	_	_	_	_
9-9	1358-1364	reduce	_	_	_	_
9-10	1365-1368	ROS	substance|abstract[67]	giv|new[67]	_	_
9-11	1369-1379	production	abstract[67]	new[67]	_	_
9-12	1380-1383	and	_	_	_	_
9-13	1384-1400	pro-inflammatory	abstract[70]	new[70]	appos	9-18[0_70]
9-14	1401-1406	tumor	abstract|abstract[70]	new|new[70]	_	_
9-15	1407-1415	necrosis	abstract|abstract[70]	new|new[70]	_	_
9-16	1416-1424	factor-α	abstract[70]	new[70]	_	_
9-17	1425-1426	(	_	_	_	_
9-18	1427-1432	TNF-α	abstract	giv	_	_
9-19	1433-1434	)	_	_	_	_
9-20	1435-1444	secretion	abstract[72]	new[72]	_	_
9-21	1445-1447	in	abstract[72]	new[72]	_	_
9-22	1448-1449	a	abstract[72]|abstract[74]	new[72]|giv[74]	_	_
9-23	1450-1453	rat	abstract[72]|animal|abstract[74]	new[72]|new|giv[74]	_	_
9-24	1454-1459	model	abstract[72]|abstract[74]	new[72]|giv[74]	_	_
9-25	1460-1462	of	abstract[72]|abstract[74]	new[72]|giv[74]	_	_
9-26	1463-1468	acute	abstract[72]|abstract[74]|abstract[75]	new[72]|giv[74]|new[75]	_	_
9-27	1469-1476	uveitis	abstract[72]|abstract[74]|abstract[75]	new[72]|giv[74]|new[75]	_	_
9-28	1477-1484	induced	_	_	_	_
9-29	1485-1487	by	_	_	_	_
9-30	1488-1506	lipopolysaccharide	substance[76]	new[76]	_	_
9-31	1507-1516	injection	substance[76]	new[76]	_	_
9-32	1517-1518	.	_	_	_	_

#Text=These previous findings imply that Ech A could exert a wide range of therapeutic impacts on other oxidative stress-related and inflammatory pathologic conditions ; however , the cell-type specific regulation of Ech A on the immune system , which consists of various innate and adaptive immune cells , has not been elucidated yet .
10-1	1519-1524	These	abstract[77]	new[77]	coref	17-1[150_77]
10-2	1525-1533	previous	abstract[77]	new[77]	_	_
10-3	1534-1542	findings	abstract[77]	new[77]	_	_
10-4	1543-1548	imply	_	_	_	_
10-5	1549-1553	that	_	_	_	_
10-6	1554-1557	Ech	substance[78]	giv[78]	coref	10-32[0_78]
10-7	1558-1559	A	substance[78]	giv[78]	_	_
10-8	1560-1565	could	_	_	_	_
10-9	1566-1571	exert	_	_	_	_
10-10	1572-1573	a	abstract[79]	new[79]	_	_
10-11	1574-1578	wide	abstract[79]	new[79]	_	_
10-12	1579-1584	range	abstract[79]	new[79]	_	_
10-13	1585-1587	of	abstract[79]	new[79]	_	_
10-14	1588-1599	therapeutic	abstract[79]|abstract[80]	new[79]|new[80]	_	_
10-15	1600-1607	impacts	abstract[79]|abstract[80]	new[79]|new[80]	_	_
10-16	1608-1610	on	abstract[79]|abstract[80]	new[79]|new[80]	_	_
10-17	1611-1616	other	abstract[79]|abstract[80]|abstract[82]	new[79]|new[80]|new[82]	appos	10-25[83_82]
10-18	1617-1626	oxidative	abstract[79]|abstract[80]|place|abstract[82]	new[79]|new[80]|new|new[82]	_	_
10-19	1627-1641	stress-related	abstract[79]|abstract[80]|abstract[82]	new[79]|new[80]|new[82]	_	_
10-20	1642-1645	and	abstract[79]|abstract[80]|abstract[82]	new[79]|new[80]|new[82]	_	_
10-21	1646-1658	inflammatory	abstract[79]|abstract[80]|abstract[82]	new[79]|new[80]|new[82]	_	_
10-22	1659-1669	pathologic	abstract[79]|abstract[80]|abstract[82]	new[79]|new[80]|new[82]	_	_
10-23	1670-1680	conditions	abstract[79]|abstract[80]|abstract[82]	new[79]|new[80]|new[82]	_	_
10-24	1681-1682	;	_	_	_	_
10-25	1683-1690	however	abstract[83]	giv[83]	_	_
10-26	1691-1692	,	abstract[83]	giv[83]	_	_
10-27	1693-1696	the	abstract[83]	giv[83]	_	_
10-28	1697-1706	cell-type	abstract[83]	giv[83]	_	_
10-29	1707-1715	specific	abstract[83]	giv[83]	_	_
10-30	1716-1726	regulation	abstract[83]	giv[83]	_	_
10-31	1727-1729	of	abstract[83]	giv[83]	_	_
10-32	1730-1733	Ech	abstract[83]|abstract	giv[83]|giv	coref	16-7[137_0]
10-33	1734-1735	A	abstract[83]|abstract[85]	giv[83]|new[85]	_	_
10-34	1736-1738	on	abstract[83]|abstract[85]	giv[83]|new[85]	_	_
10-35	1739-1742	the	abstract[83]|abstract[85]	giv[83]|new[85]	_	_
10-36	1743-1749	immune	abstract[83]|abstract[85]	giv[83]|new[85]	_	_
10-37	1750-1756	system	abstract[83]|abstract[85]	giv[83]|new[85]	_	_
10-38	1757-1758	,	_	_	_	_
10-39	1759-1764	which	_	_	_	_
10-40	1765-1773	consists	_	_	_	_
10-41	1774-1776	of	_	_	_	_
10-42	1777-1784	various	object[86]	new[86]	coref	16-20[142_86]
10-43	1785-1791	innate	object[86]	new[86]	_	_
10-44	1792-1795	and	object[86]	new[86]	_	_
10-45	1796-1804	adaptive	object[86]	new[86]	_	_
10-46	1805-1811	immune	object[86]	new[86]	_	_
10-47	1812-1817	cells	object[86]	new[86]	_	_
10-48	1818-1819	,	_	_	_	_
10-49	1820-1823	has	_	_	_	_
10-50	1824-1827	not	_	_	_	_
10-51	1828-1832	been	_	_	_	_
10-52	1833-1843	elucidated	_	_	_	_
10-53	1844-1847	yet	_	_	_	_
10-54	1848-1849	.	_	_	_	_

#Text=Inflammatory bowel disease ( IBD ) is an intractable , chronic inflammatory disease of the digestive tract and Crohn 's disease ( CD ) and ulcerative colitis ( UC ) are the major types of IBD .
11-1	1850-1862	Inflammatory	abstract[88]	new[88]	appos	11-5[0_88]
11-2	1863-1868	bowel	object|abstract[88]	new|new[88]	_	_
11-3	1869-1876	disease	abstract[88]	new[88]	_	_
11-4	1877-1878	(	_	_	_	_
11-5	1879-1882	IBD	abstract	giv	coref	11-8[90_0]
11-6	1883-1884	)	_	_	_	_
11-7	1885-1887	is	_	_	_	_
11-8	1888-1890	an	abstract[90]	giv[90]	coref	12-7[0_90]
11-9	1891-1902	intractable	abstract[90]	giv[90]	_	_
11-10	1903-1904	,	abstract[90]	giv[90]	_	_
11-11	1905-1912	chronic	abstract[90]	giv[90]	_	_
11-12	1913-1925	inflammatory	abstract[90]	giv[90]	_	_
11-13	1926-1933	disease	abstract[90]	giv[90]	_	_
11-14	1934-1936	of	abstract[90]	giv[90]	_	_
11-15	1937-1940	the	abstract[90]|place[91]	giv[90]|new[91]	_	_
11-16	1941-1950	digestive	abstract[90]|place[91]	giv[90]|new[91]	_	_
11-17	1951-1956	tract	abstract[90]|place[91]	giv[90]|new[91]	_	_
11-18	1957-1960	and	abstract[90]	giv[90]	_	_
11-19	1961-1966	Crohn	abstract[90]|person[92]|abstract[93]	giv[90]|new[92]|giv[93]	appos|appos	11-23[0_93]|11-23[0_93]
11-20	1967-1969	's	abstract[90]|person[92]|abstract[93]	giv[90]|new[92]|giv[93]	_	_
11-21	1970-1977	disease	abstract[90]|abstract[93]	giv[90]|giv[93]	_	_
11-22	1978-1979	(	abstract[90]	giv[90]	_	_
11-23	1980-1982	CD	abstract[90]|abstract	giv[90]|giv	_	_
11-24	1983-1984	)	abstract[90]	giv[90]	_	_
11-25	1985-1988	and	abstract[90]	giv[90]	_	_
11-26	1989-1999	ulcerative	abstract[90]|abstract|abstract[96]	giv[90]|new|new[96]	appos|appos	11-29[0_96]|11-29[0_96]
11-27	2000-2007	colitis	abstract[90]|abstract[96]	giv[90]|new[96]	_	_
11-28	2008-2009	(	abstract[90]	giv[90]	_	_
11-29	2010-2012	UC	abstract[90]|abstract	giv[90]|giv	_	_
11-30	2013-2014	)	abstract[90]	giv[90]	_	_
11-31	2015-2018	are	abstract[90]	giv[90]	_	_
11-32	2019-2022	the	abstract[90]|abstract[98]	giv[90]|new[98]	_	_
11-33	2023-2028	major	abstract[90]|abstract[98]	giv[90]|new[98]	_	_
11-34	2029-2034	types	abstract[90]|abstract[98]	giv[90]|new[98]	_	_
11-35	2035-2037	of	abstract[90]|abstract[98]	giv[90]|new[98]	_	_
11-36	2038-2041	IBD	abstract[90]|abstract[98]	giv[90]|new[98]	_	_
11-37	2042-2043	.	_	_	_	_

#Text=The etiology and pathogenic mechanisms of IBD remain largely unknown and both environmental factors and genetic factors combined with immunological dysfunction seem to drive IBD development .
12-1	2044-2047	The	abstract[99]	new[99]	_	_
12-2	2048-2056	etiology	abstract[99]	new[99]	_	_
12-3	2057-2060	and	_	_	_	_
12-4	2061-2071	pathogenic	abstract[100]	new[100]	_	_
12-5	2072-2082	mechanisms	abstract[100]	new[100]	_	_
12-6	2083-2085	of	abstract[100]	new[100]	_	_
12-7	2086-2089	IBD	abstract[100]|event	new[100]|giv	coref	12-25
12-8	2090-2096	remain	_	_	_	_
12-9	2097-2104	largely	_	_	_	_
12-10	2105-2112	unknown	_	_	_	_
12-11	2113-2116	and	_	_	_	_
12-12	2117-2121	both	abstract[102]	new[102]	_	_
12-13	2122-2135	environmental	abstract[102]	new[102]	_	_
12-14	2136-2143	factors	abstract[102]	new[102]	_	_
12-15	2144-2147	and	_	_	_	_
12-16	2148-2155	genetic	abstract[103]	new[103]	_	_
12-17	2156-2163	factors	abstract[103]	new[103]	_	_
12-18	2164-2172	combined	_	_	_	_
12-19	2173-2177	with	_	_	_	_
12-20	2178-2191	immunological	abstract[104]	new[104]	_	_
12-21	2192-2203	dysfunction	abstract[104]	new[104]	_	_
12-22	2204-2208	seem	_	_	_	_
12-23	2209-2211	to	_	_	_	_
12-24	2212-2217	drive	_	_	_	_
12-25	2218-2221	IBD	abstract|event[106]	giv|new[106]	coref|coref	14-18|14-18
12-26	2222-2233	development	event[106]	new[106]	_	_
12-27	2234-2235	.	_	_	_	_

#Text=To attenuate the excessive immune response , advanced immunotherapy using immune-modulators such as inflammatory cytokine blockers has been used recently ; however , the presence of non-responder and uncontrolled side effects are the common challenging issues when using immunotherapy .
13-1	2236-2238	To	_	_	_	_
13-2	2239-2248	attenuate	_	_	_	_
13-3	2249-2252	the	event[108]	new[108]	_	_
13-4	2253-2262	excessive	event[108]	new[108]	_	_
13-5	2263-2269	immune	abstract|event[108]	new|new[108]	_	_
13-6	2270-2278	response	event[108]	new[108]	_	_
13-7	2279-2280	,	_	_	_	_
13-8	2281-2289	advanced	abstract[109]	new[109]	coref	13-39[0_109]
13-9	2290-2303	immunotherapy	abstract[109]	new[109]	_	_
13-10	2304-2309	using	_	_	_	_
13-11	2310-2327	immune-modulators	abstract[110]	new[110]	_	_
13-12	2328-2332	such	abstract[110]	new[110]	_	_
13-13	2333-2335	as	abstract[110]	new[110]	_	_
13-14	2336-2348	inflammatory	abstract[110]|object[112]	new[110]|new[112]	_	_
13-15	2349-2357	cytokine	abstract[110]|abstract|object[112]	new[110]|new|new[112]	_	_
13-16	2358-2366	blockers	abstract[110]|object[112]	new[110]|new[112]	_	_
13-17	2367-2370	has	_	_	_	_
13-18	2371-2375	been	_	_	_	_
13-19	2376-2380	used	_	_	_	_
13-20	2381-2389	recently	_	_	_	_
13-21	2390-2391	;	_	_	_	_
13-22	2392-2399	however	_	_	_	_
13-23	2400-2401	,	_	_	_	_
13-24	2402-2405	the	abstract[113]	new[113]	_	_
13-25	2406-2414	presence	abstract[113]	new[113]	_	_
13-26	2415-2417	of	abstract[113]	new[113]	_	_
13-27	2418-2431	non-responder	abstract[113]|abstract[115]	new[113]|giv[115]	_	_
13-28	2432-2435	and	abstract[113]|abstract[115]	new[113]|giv[115]	_	_
13-29	2436-2448	uncontrolled	abstract[113]|abstract[115]	new[113]|giv[115]	_	_
13-30	2449-2453	side	abstract[113]|abstract|abstract[115]	new[113]|new|giv[115]	_	_
13-31	2454-2461	effects	abstract[113]|abstract[115]	new[113]|giv[115]	_	_
13-32	2462-2465	are	_	_	_	_
13-33	2466-2469	the	abstract[116]	new[116]	_	_
13-34	2470-2476	common	abstract[116]	new[116]	_	_
13-35	2477-2488	challenging	abstract[116]	new[116]	_	_
13-36	2489-2495	issues	abstract[116]	new[116]	_	_
13-37	2496-2500	when	_	_	_	_
13-38	2501-2506	using	_	_	_	_
13-39	2507-2520	immunotherapy	abstract	giv	_	_
13-40	2521-2522	.	_	_	_	_

#Text=Therefore , there has been an unmet need to develop novel therapeutics for the effective management of IBD .
14-1	2523-2532	Therefore	_	_	_	_
14-2	2533-2534	,	_	_	_	_
14-3	2535-2540	there	_	_	_	_
14-4	2541-2544	has	_	_	_	_
14-5	2545-2549	been	_	_	_	_
14-6	2550-2552	an	abstract[118]	new[118]	_	_
14-7	2553-2558	unmet	abstract[118]	new[118]	_	_
14-8	2559-2563	need	abstract[118]	new[118]	_	_
14-9	2564-2566	to	_	_	_	_
14-10	2567-2574	develop	_	_	_	_
14-11	2575-2580	novel	abstract[119]	new[119]	_	_
14-12	2581-2593	therapeutics	abstract[119]	new[119]	_	_
14-13	2594-2597	for	_	_	_	_
14-14	2598-2601	the	abstract[120]	new[120]	_	_
14-15	2602-2611	effective	abstract[120]	new[120]	_	_
14-16	2612-2622	management	abstract[120]	new[120]	_	_
14-17	2623-2625	of	abstract[120]	new[120]	_	_
14-18	2626-2629	IBD	abstract[120]|event	new[120]|giv	coref	15-16
14-19	2630-2631	.	_	_	_	_

#Text=In this study , we investigated whether Ech A could exhibit a protective role in IBD progression using a chemical colitogen dextran sodium sulfate ( DSS)-induced colitis mice model .
15-1	2632-2634	In	_	_	_	_
15-2	2635-2639	this	abstract[122]	giv[122]	_	_
15-3	2640-2645	study	abstract[122]	giv[122]	_	_
15-4	2646-2647	,	_	_	_	_
15-5	2648-2650	we	person	acc	ana	16-10
15-6	2651-2663	investigated	_	_	_	_
15-7	2664-2671	whether	_	_	_	_
15-8	2672-2675	Ech	person	giv	_	_
15-9	2676-2677	A	_	_	_	_
15-10	2678-2683	could	_	_	_	_
15-11	2684-2691	exhibit	_	_	_	_
15-12	2692-2693	a	abstract[125]	new[125]	_	_
15-13	2694-2704	protective	abstract[125]	new[125]	_	_
15-14	2705-2709	role	abstract[125]	new[125]	_	_
15-15	2710-2712	in	abstract[125]	new[125]	_	_
15-16	2713-2716	IBD	abstract[125]|event|event[127]	new[125]|giv|new[127]	coref|coref	17-31|17-31
15-17	2717-2728	progression	abstract[125]|event[127]	new[125]|new[127]	_	_
15-18	2729-2734	using	_	_	_	_
15-19	2735-2736	a	abstract[131]	new[131]	appos	15-26[135_131]
15-20	2737-2745	chemical	abstract[131]	new[131]	_	_
15-21	2746-2755	colitogen	substance|abstract[131]	new|new[131]	_	_
15-22	2756-2763	dextran	person|abstract[131]	new|new[131]	_	_
15-23	2764-2770	sodium	substance|abstract[131]	new|new[131]	_	_
15-24	2771-2778	sulfate	abstract[131]	new[131]	_	_
15-25	2779-2780	(	_	_	_	_
15-26	2781-2793	DSS)-induced	abstract|abstract[135]	new|giv[135]	coref|coref	17-26[156_135]|17-26[156_135]
15-27	2794-2801	colitis	person|abstract[135]	new|giv[135]	coref	17-27
15-28	2802-2806	mice	animal|abstract[135]	new|giv[135]	_	_
15-29	2807-2812	model	abstract[135]	giv[135]	_	_
15-30	2813-2814	.	_	_	_	_

#Text=To explore the therapeutic mechanism of Ech A , we also performed in vitro proliferation and polarization experiments with two major innate and adaptive immune cells , macrophage and CD4+ helper T cells ( Th cells ) , respectively .
16-1	2815-2817	To	_	_	_	_
16-2	2818-2825	explore	_	_	_	_
16-3	2826-2829	the	abstract[136]	new[136]	_	_
16-4	2830-2841	therapeutic	abstract[136]	new[136]	_	_
16-5	2842-2851	mechanism	abstract[136]	new[136]	_	_
16-6	2852-2854	of	abstract[136]	new[136]	_	_
16-7	2855-2858	Ech	abstract[136]|abstract[137]	new[136]|giv[137]	coref	17-7[151_137]
16-8	2859-2860	A	abstract[136]|abstract[137]	new[136]|giv[137]	_	_
16-9	2861-2862	,	_	_	_	_
16-10	2863-2865	we	person	giv	ana	17-1
16-11	2866-2870	also	_	_	_	_
16-12	2871-2880	performed	_	_	_	_
16-13	2881-2883	in	_	_	_	_
16-14	2884-2889	vitro	abstract[139]	new[139]	_	_
16-15	2890-2903	proliferation	abstract[139]	new[139]	_	_
16-16	2904-2907	and	_	_	_	_
16-17	2908-2920	polarization	abstract|event[141]	new|new[141]	_	_
16-18	2921-2932	experiments	event[141]	new[141]	_	_
16-19	2933-2937	with	event[141]	new[141]	_	_
16-20	2938-2941	two	event[141]|object[142]	new[141]|giv[142]	coref	16-30[146_142]
16-21	2942-2947	major	event[141]|object[142]	new[141]|giv[142]	_	_
16-22	2948-2954	innate	event[141]|object[142]	new[141]|giv[142]	_	_
16-23	2955-2958	and	event[141]|object[142]	new[141]|giv[142]	_	_
16-24	2959-2967	adaptive	event[141]|object[142]	new[141]|giv[142]	_	_
16-25	2968-2974	immune	event[141]|object[142]	new[141]|giv[142]	_	_
16-26	2975-2980	cells	event[141]|object[142]	new[141]|giv[142]	_	_
16-27	2981-2982	,	event[141]|object[142]	new[141]|giv[142]	_	_
16-28	2983-2993	macrophage	event[141]|object[142]|abstract	new[141]|giv[142]|new	_	_
16-29	2994-2997	and	_	_	_	_
16-30	2998-3002	CD4+	abstract|object[146]	new|giv[146]	appos|appos	16-35[147_146]|16-35[147_146]
16-31	3003-3009	helper	object[146]	giv[146]	_	_
16-32	3010-3011	T	person|object[146]	new|giv[146]	_	_
16-33	3012-3017	cells	object[146]	giv[146]	_	_
16-34	3018-3019	(	_	_	_	_
16-35	3020-3022	Th	object[147]	giv[147]	coref	18-23[162_147]
16-36	3023-3028	cells	object[147]	giv[147]	_	_
16-37	3029-3030	)	_	_	_	_
16-38	3031-3032	,	_	_	_	_
16-39	3033-3045	respectively	_	_	_	_
16-40	3046-3047	.	_	_	_	_

#Text=Our in vivo findings suggest that Ech A could attenuate the clinical signs , as well as histological improvement , for the first time in a colitis model which represents IBD .
17-1	3048-3051	Our	person|abstract[150]	giv|giv[150]	_	_
17-2	3052-3054	in	abstract[150]	giv[150]	_	_
17-3	3055-3059	vivo	abstract|abstract[150]	new|giv[150]	_	_
17-4	3060-3068	findings	abstract[150]	giv[150]	_	_
17-5	3069-3076	suggest	_	_	_	_
17-6	3077-3081	that	_	_	_	_
17-7	3082-3085	Ech	substance[151]	giv[151]	coref	18-13[0_151]
17-8	3086-3087	A	substance[151]	giv[151]	_	_
17-9	3088-3093	could	_	_	_	_
17-10	3094-3103	attenuate	_	_	_	_
17-11	3104-3107	the	abstract[152]	new[152]	_	_
17-12	3108-3116	clinical	abstract[152]	new[152]	_	_
17-13	3117-3122	signs	abstract[152]	new[152]	_	_
17-14	3123-3124	,	_	_	_	_
17-15	3125-3127	as	_	_	_	_
17-16	3128-3132	well	_	_	_	_
17-17	3133-3135	as	_	_	_	_
17-18	3136-3148	histological	abstract[153]	new[153]	_	_
17-19	3149-3160	improvement	abstract[153]	new[153]	_	_
17-20	3161-3162	,	_	_	_	_
17-21	3163-3166	for	_	_	_	_
17-22	3167-3170	the	abstract[154]	new[154]	_	_
17-23	3171-3176	first	abstract[154]	new[154]	_	_
17-24	3177-3181	time	abstract[154]	new[154]	_	_
17-25	3182-3184	in	abstract[154]	new[154]	_	_
17-26	3185-3186	a	abstract[154]|abstract[156]	new[154]|giv[156]	_	_
17-27	3187-3194	colitis	abstract[154]|person|abstract[156]	new[154]|giv|giv[156]	_	_
17-28	3195-3200	model	abstract[154]|abstract[156]	new[154]|giv[156]	_	_
17-29	3201-3206	which	_	_	_	_
17-30	3207-3217	represents	_	_	_	_
17-31	3218-3221	IBD	abstract	giv	_	_
17-32	3222-3223	.	_	_	_	_

#Text=More importantly , in vitro results demonstrate that the anti-inflammatory function of Ech A is manifested by , in part , inducing immunomodulatory effector cells , such as M2 macrophages and Treg cells .
18-1	3224-3228	More	_	_	_	_
18-2	3229-3240	importantly	_	_	_	_
18-3	3241-3242	,	_	_	_	_
18-4	3243-3245	in	_	_	_	_
18-5	3246-3251	vitro	abstract[158]	new[158]	_	_
18-6	3252-3259	results	abstract[158]	new[158]	_	_
18-7	3260-3271	demonstrate	_	_	_	_
18-8	3272-3276	that	_	_	_	_
18-9	3277-3280	the	abstract[159]	new[159]	_	_
18-10	3281-3298	anti-inflammatory	abstract[159]	new[159]	_	_
18-11	3299-3307	function	abstract[159]	new[159]	_	_
18-12	3308-3310	of	abstract[159]	new[159]	_	_
18-13	3311-3314	Ech	abstract[159]|abstract	new[159]|giv	_	_
18-14	3315-3316	A	abstract[159]	new[159]	_	_
18-15	3317-3319	is	_	_	_	_
18-16	3320-3330	manifested	_	_	_	_
18-17	3331-3333	by	_	_	_	_
18-18	3334-3335	,	_	_	_	_
18-19	3336-3338	in	_	_	_	_
18-20	3339-3343	part	_	_	_	_
18-21	3344-3345	,	_	_	_	_
18-22	3346-3354	inducing	_	_	_	_
18-23	3355-3371	immunomodulatory	object[162]	giv[162]	_	_
18-24	3372-3380	effector	person|object[162]	new|giv[162]	_	_
18-25	3381-3386	cells	object[162]	giv[162]	_	_
18-26	3387-3388	,	object[162]	giv[162]	_	_
18-27	3389-3393	such	object[162]	giv[162]	_	_
18-28	3394-3396	as	object[162]	giv[162]	_	_
18-29	3397-3399	M2	object[162]|abstract|object[164]	giv[162]|new|new[164]	_	_
18-30	3400-3411	macrophages	object[162]|object[164]	giv[162]|new[164]	_	_
18-31	3412-3415	and	object[162]	giv[162]	_	_
18-32	3416-3420	Treg	object[162]|object	giv[162]|new	_	_
18-33	3421-3426	cells	object[162]	giv[162]	_	_
18-34	3427-3428	.	_	_	_	_
